References
- Bax BD, Chan PF, Eggleston DS, et al. (2010). Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466:935–40
- Boucher HW, Talbot GH, Bradley JS, et al. (2009). Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12
- Garner RC, Barker J, Flavell C, et al. (2000). A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14 C-labelled drugs in plasma, urine and faecal extracts. J Pharma Biomed Anal 24:197–209
- Guiney WJ, Beaumont C, Thomas SR, et al. (2011). Use of Entero-Test, a simple approach for non-invasive clinical evaluation of the biliary disposition of drugs. Br J Clin Pharmacol 72:133–42
- Hop CE, Wang Z, Chen Q, Kwei G. (1998). Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901–3
- ICRP. (1991). 1990 Recommendations of the International Commission on Radiological Protection. ICRP Publication 60. Ann ICRP 21:1–3
- ICRP. (1992). Radiological protection in biomedical research. ICRP Publication 62. Ann ICRP 22:1–18
- Oliveira EJ, Watson DG. (2000). Liquid chromatography-mass spectrometry in the study of the metabolism of drugs and other xenobiotics. Biomed Chromatogr 14:351–72
- Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. (2007). Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6:29–40
- Pearson ND, Gwynn MN. (2013) Exploiting novel bacterial topoisomerase inhibitors (NBTIs) as a new class of antibiotic. American Chemical Society, Division of Medicinal Chemistry Scientific Abstracts for the 246th National Meeting and Exposition; 2013 Sep 8–12, 2013; Indianapolis, IN, USA
- Pryde DC, Dalvie D, Hu Q, et al. (2010). Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 53:8441–60
- Roffey SJ, Obach RS, Gedge JI, Smith DA. (2007). What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 39:17–43
- Strelevitz T, Orozco C, Obach RS. (2012). Hydralazine as a selective probe inactivation of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance. Drug Metab Dispos 40:1441–8
- Testa B, Mihailova D. (1978). An ab initio study of electronic factors in metabolic hydroxylation of aliphatic carbon atoms. J Med Chem 21:683–6
- Testa B, Mihailova D, Natacheva R. (1979). Electronic indices of alkyl substituents undergoing regioselective metabolic hydroxylation. Eur J Med Chem 14:295–9
- World Health Organization. (1977). Use of ionising radiation and radionuclides on human beings for medical research, training and nonmedical purposes. Technical Report Series No. 611. Geneva: World Health Organization
- Young GC, Corless S, Felgate CC, Colthup PV. (2008). Comparison of a 250 kV single-stage accelerator mass spectrometer with a 5 MV tandem accelerator mass spectrometer – fitness for purpose in bioanalysis. Rapid Commun Mass Spectrom 22:4035–42